Showing 1541-1550 of 1638 results for "".
- New Survey Finds Social Media is a Major Influence on Elective Surgeryhttps://practicaldermatology.com/news/20130327-new_survey_finds_social_media_is_a_major_influence_on_elective_surgery/2459578/Social media is leading consumers to have a more self-critical eye, according to a new survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). The annual poll of the organization's board-certified facial plastic surgeons found a 31 percent increase in requests for surge
- Skin Cancer Foundation Inducts Dr. Amy Forman Taub into its Amonette Circlehttps://practicaldermatology.com/news/20130327-skin_cancer_foundation_inducts_amy_forman_taub_md_into_its_amonette_circle/2459579/Amy Forman Taub, MD, was recently inducted into the Skin Cancer Foundation's Amonette Circle at the American Academy of Dermatology Annual Meeting in Miami, FL. Amonette Circle is a lifetime membership comprised of physicians who make an outstanding commitment to The Skin Cancer Foundation's mission
- Merz to Absorb Costs of New Excise Tax on Certain Medical Deviceshttps://practicaldermatology.com/news/20130321-merz_to_absord_costs_of_new_excise_tax_on_medical_devices/2459580/Merz Aesthetics announced that it does not intend to raise prices on medical devices, despite the new excise tax on the sale of certain medical devices of about 2.3 percent now going into effect, per the Patient Protection and Affordable Care Act. In a statement to clients and potential clients, Mer
- Valeant Pharmaceuticals to Acquire Obagi Medical Products for Approximately $344 Millionhttps://practicaldermatology.com/news/20130320-valeant_pharmaceuticals_to_acquire_obagi_medical_products_for_approximately_360_million/2459581/Valeant Pharmaceuticals has entered into an agreement to acquire Obagi Medical Products. The transaction values Obagi common stock at approximately $344 million and was unanimously approved by the Obagi Board of Directors. Under terms of the merger agreement, Valeant will commence a tender offer for
- Dermablend Launches Concealer and Highlighter for Clearer Complexionhttps://practicaldermatology.com/news/20130314-dermablend_launches_concealer_and_highlighter_for_clearer_complexion/2459590/Dermablend's new Quick-Fix Illuminator is a multi-purpose concealer and highlighter that can conceal, smooth, illuminate, brighten, highlight and sculpt the face for an improved complexion. According to the company, the Quick-Fix Illuminator is safe for even the most sensitive skin diminishes dark c
- Galderma Launches Online Epiduo Adherence Programhttps://practicaldermatology.com/news/20130312-galderma_launches_online_epiduo_adherence_program/2459593/Galderma announced its new Epiduo TAP (Treatment, Adherence, and Performance) Program, an online and mobile patient platform that educates acne patients ages 13 and older about the proper application of Epiduo (adapalene and benzoyl peroxide 0.1%/2.5%) Gel and encourages acne patients to stay adhere
- Envy Medical Unveils New Acne Systemhttps://practicaldermatology.com/news/20130311-envy_medical_unveils_new_acne_system/2459595/Envy Medical Inc. recently launched the ClarityMD Acne Solution at the American Academy of Dermatology Annual Meeting on March 1 in Miami. The system includes a Deep Pore Cleanser and Clarifying Gel in a two-step system that's clinically proven to significantly heal acne within days, according to th
- AAD Unveils New App for Diagnosing and Treating Psoriasishttps://practicaldermatology.com/news/20130311-aad_unveils_new_app_for_diagnosing_and_treating_psoriasis/2459599/At its recent annual meeting in Miami, The American Academy of Dermatology introduced a mobile app of evidence-based clinical guidelines for diagnosing and treating psoriasis and psoriatic arthritis. The free app includes a clinical decision tree; reference guide for diagnoses; arthritic diagnostic
- Naftifine Gel Found Effective for Moccasin-Type Tinea Pedishttps://practicaldermatology.com/news/20130307-naftifine_gel_found_effective_for_moccasin-type_tinea_pedis/2459600/New data has found that the topical antifungal agent naftifine hydrochloride gel 2% (Merz North America) is both efficacious and tolerable in the treatment for interdigital-type and moccasin-type Tinea pedis. In a poster presented at the AAD Annual Meeting in Miami, the authored sounds that naftifin
- Medical Entrepreneur Symposium: Registration Open, Sponsors Invitedhttps://practicaldermatology.com/news/20130226-medical_entrepreneur_symposium_registration_open_sponsors_invited/2459606/The 2nd Annual The Medical Entrepreneur Symposium for physicians, office managers and physician entrepreneurs, to be held in Delray Beach, FL April 19-21, is expected to attract over 150 healthcare (and healthcare related) professionals an